SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

Antibodies targeting the spike protein of coronaviruses are potential candidates for therapeutic development. Here, Bertoglio et al. use phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve universal antibody gene libraries HAL9/10 that block interaction with ACE2 receptor t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Federico Bertoglio, Doris Meier, Nora Langreder, Stephan Steinke, Ulfert Rand, Luca Simonelli, Philip Alexander Heine, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, Maximilian Ruschig, Peggy Riese, Kathrin Eschke, Yeonsu Kim, Dorina Schäckermann, Mattia Pedotti, Philipp Kuhn, Susanne Zock-Emmenthal, Johannes Wöhrle, Normann Kilb, Tobias Herz, Marlies Becker, Martina Grasshoff, Esther Veronika Wenzel, Giulio Russo, Andrea Kröger, Linda Brunotte, Stephan Ludwig, Viola Fühner, Stefan Daniel Krämer, Stefan Dübel, Luca Varani, Günter Roth, Luka Čičin-Šain, Maren Schubert, Michael Hust
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/0dc5d5dbf361487e9f729846cf72c808
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Antibodies targeting the spike protein of coronaviruses are potential candidates for therapeutic development. Here, Bertoglio et al. use phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve universal antibody gene libraries HAL9/10 that block interaction with ACE2 receptor to inhibit infection.

Ejemplares similares